How would you measure the success of Pfizer's Prevnar 13 vaccine?

Introduction

Measuring the success of Pfizer's Prevnar 13 vaccine requires a comprehensive approach that considers multiple stakeholders and factors. To address this product success metrics challenge, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Prevnar 13 is a pneumococcal conjugate vaccine developed by Pfizer to prevent invasive pneumococcal disease caused by 13 strains of Streptococcus pneumoniae. It's primarily administered to infants, young children, and adults over 65.

Key stakeholders include:

• Patients (infants, children, elderly)
• Healthcare providers
• Public health organizations
• Pfizer shareholders
• Regulatory bodies (FDA, EMA)

User flow:

1. Healthcare provider recommends vaccine
2. Patient/guardian consents
3. Vaccine administered in series (typically 4 doses for children)
4. Follow-up monitoring for effectiveness and side effects

Prevnar 13 fits into Pfizer's broader strategy of developing innovative vaccines to address global health challenges. It's a key product in their vaccine portfolio, contributing significantly to revenue and public health impact.

Competitors include Merck's Pneumovax 23, which covers more strains but is less effective in young children. Prevnar 13's conjugate technology gives it an edge in efficacy for certain age groups.

Product Lifecycle Stage: Mature. Prevnar 13 has been on the market since 2010 and is widely adopted, but still faces challenges in expanding global access and adapting to emerging pneumococcal strains.

Physical Product Considerations:

• Distribution channels: Primarily through healthcare systems and pharmacies
• Shelf-life: Typically 2-3 years when properly stored
• Sales model: Bulk purchases by healthcare systems and governments